We explore the evidence that informs ambulatory care pharmacy practice. Check out our website & podcasts, & consider submitting a commentary!
Episodes
Oct 16, 2015
Oct 16, 2015
8 min
The recommended treatment duration for a first episode of unprovoked venous thromboembolism (VTE) is, at a minimum, 3 months with extended anticoagulation favored for those who are not at high risk for bleeding. However, the optimal duration of anticoagulation therapy remains unknown. The Prolonged Anticoagulation Treatment for a First Episode of Idiopathic Pulmonary Embolism (PADIS-PE) study examines this question but, most importantly, provides insights about patient outcomes after anticoagulation treatment is discontinued
Sep 5, 2015
Sep 5, 2015
9 min
Two new mAbs, alirocumab and evolocumab, have been approved to treat elevated cholesterol when added to maximally tolerated statin therapy in patients with familial hypercholesterolemia or history of atherosclerotic cardiovascular disease (ASCVD). This new class of drugs, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, is considered to be the biggest breakthrough in cholesterol treatment since statins were approved 3 decades ago. But are they worth it?
Jul 28, 2015
Jul 28, 2015
9 min
How well do cardiovascular disease risk calculators really perform? Do they over or underestimate risk? Should we rely on them to make treatment decisions?
Jun 21, 2015
Jun 21, 2015
15 min
Our guests - Dr. Cortney Mospan and Dr. Augustus (Rob) Hough - critically examine the results of the DAPT and PEGASUS-TIMI 54 studies and explain how the results should be applied in practice.
Feb 16, 2015
Feb 16, 2015
8 min
Guidelines promote the use of statins as first line therapy to prevent atherosclerotic cardiovascular disease events. Does adding niacin to statin treatment reduce residual risk?